Elranatamab With Mezigdomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
GEM-MeziDEL
Multicenter, Open Label, Phase II Clinical Trial Evaluating the Combination of Elranatamab With Mezigdomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Primary Completion
December 2031
Estimated
Planned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
December 2032
Estimated
Planned date reported by the registry; this milestone is not confirmed as achieved.
Brief Summary
The goal of this clinical trial is to learn if the drug combination Elranatamab plus Mezigdomide plus Dexametahsone works to cure patients with relapsed/refractory multiple myeloma.
The main questions it aims to answer are:
Do participants receiving Elranatamab plus Mezigdomide plus Dexametahsone achieve optimal treatment response by showing negative minimal residual disease at the end of treatment?
By evaluating the incidence of adverse events and severe adverse events, is this drug combination tolerable for participants?
All participants will receive 1 cycle of Elranatamab plus Dexamethasone followed by 5 cycles of Elranatamab plus Mezigdomide plus Dexamethasone, and 6 cycles of Elranatamab plus Mezigdomide. At this timepoint (end of cycle 12), the level of minimal residual disease will be assessed to decide if patients receive Mezigdomide alone as maintenance (for patients with negative minimal residual disease), or continue reciving Elranatamab plus Mezigdomide.
Registry Overview
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
Recruitment status
not yet recruiting
Estimated enrollment
60 participants
Study completion date
December 2032
Estimated
Planned date reported by the registry; this milestone is not confirmed as achieved.
Listed locations
1 country20 listed sites
Trial Relationships
Click on a node to explore related trials.
Related Scientific Literature
Loading related publications...
Study Timeline
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
First Submitted
October 17, 2026
Actual (reported)
First Posted
October 28, 2026
Actual (reported)
Study Start
November 1, 2026
Estimated (date passed)
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Primary Completion
December 2031
Estimated
Planned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
December 2032
Estimated
Planned date reported by the registry; this milestone is not confirmed as achieved.
Proportion of patients achieving minimal residual disease (MRD) negativity.
To evaluate the percentage of participants achieving negative MRD. Negative MRD is defined as the presence of less than 1 tumour cell among 100,000 healthy hematopoietic cells by Next Generation Flow Cytometry in bone marrow, according to the IMWG criteria.
5 years
Secondary Outcomes (17)
Proportion of participants showing sustained MRD negativity at 24 months
5 years
Proportion of participants showing MRD negativity after early rescue intervention with elranatamab in patients on mezigdomide alone after C12.
5 years
To evaluate the Complete Response rate to elranatamab in combination with mezigdomide and dexamethasone, based on confirmed response according to the IMWG criteria.
5 years
To evaluate the Very Good Partial Response rate to elranatamab in combination with mezigdomide and dexamethasone, based on confirmed response according to the IMWG criteria.
5 years
To evaluate the Partial Response rate to elranatamab in combination with mezigdomide and dexamethasone, based on confirmed response according to the IMWG criteria.
5 years
+12 more secondary outcomes
Other Outcomes (3)
To assess the immune profile induced by elranatamab alone, the triplet combination, and treatment with mezigdomide plus dexamethasone
5 years
To assess Progression-free survival according to the quality of the response.
5 years
To assess Overall Survival according to the quality of the response.
5 years
Study Arms (2)
Negative minimal residual disease at end cycle 12
ACTIVE COMPARATOR
All participants will receive Elranatamab, Mezigdominde and Dexametahsone in 28-day cycles as follows:
* Oral Mezigdomide: dose of 0.6 mg daily on days 1 to 21 of each cycle (from cycle 2 onwards).
* Oral Dexamethasone: dose of 20 mg/day (≤ 75 years old) or 10 mg/day (\>75 years old) from cycle 1 to 6.
* Subcutaneous Elranatamab:
Cycle 1: day1 (step-up dose 12 mg), day4 (step-up dose 32 mg), day8 (target dose 76 mg), day15 (76 mg), and day22 (76 mg).
Cycles 2 and 3: day1 and day15 (76 mg) of each 28-day cycle. From cycle 4 onwards: day1 (76 mg). From Cycle 13 onwards, participants will discontinue elranatamab and will continue with mezigdomide alone.
In those patients who discontinue elranatamab due to sustained MRD negativity, Elranatamab will be reintroduced as from the cycle 2 in case of biological progression (IMWG criteria) or positivization of MRD.
Oral at a dose of 0.6 mg daily on days 1 to 21 of the 28-day cycle from C2 onwards (not in C1).
Eligibility Criteria
Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
You may qualify if:
Patient is, in the investigator's opinion, willing and able to adhere/comply with visit schedule and other protocol requirements.
b. Patient must be able to understand the study procedures. c. Patients aged ≥18 years at the time of signing the informed consent form. d. Patients have documented diagnosis of MM according to the IMWG criteria (Lancet Oncol 2014).
All participants will receive Elranatamab, Mezigdominde and Dexametahsone in 28-day cycles as follows:
* Oral Mezigdomide: dose of 0.6 mg daily on days 1 to 21 of each cycle (from cycle 2 onwards).
* Oral Dexamethasone: dose of 20 mg/day (≤ 75 years old) or 10 mg/day (\>75 years old) from cycle 1 to 6.
* Subcutaneous Elranatamab will be given as follows:
* Cycle 1: day1 (step-up dose 12 mg), day4 (step-up dose 32 mg), day8 (target dose 76 mg), day15 (76 mg), and day22 (76 mg).
* Cycles 2 and 3: day1 and day15 (76 mg) of each 28-day cycle.
* From cycle 4 onwards: day1 (76 mg).
* From Cycle 13 onwards, patients with positive minimal residual disease will keep receiving Elranatamab as from cycle 4 plus Mezigdomide with above indicated dose.
Subcutaneous Elranatamab willl be given as follows:
* Cycle 1: day1 (step-up dose 12 mg), day4 (step-up dose 32 mg), day8 (target dose 76 mg), day15 (76 mg), and D22 (76 mg) of a 28-day cycle.
* Cycles 2 and 3: day1 and day15 (76 mg) of each 28-day cycle.
* From C4 onwards: day1 (76 mg) of each 28-day cycle.
* From C13 onwards: those patients who have achieved MRD negativity sustained for at least 3 cycles, will discontinue elranatamab and will continue with mezigdomide alone as maintenance.
In those patients who discontinue elranatamab due to sustained MRD negativity, it will be reintroduced as from the cycle 2 in case of biological progression (IMWG criteria) or positivization of MRD.
Negative minimal residual disease at end cycle 12Positive minimal residual disease et end cycle 12
e. Patients have a relapsed MM who have previously received treatment with at least one line of antimyeloma therapy.
f. Patients must have documented disease progression during or after their last antimyeloma regimen.
g. Patients must have received prior treatment with a lenalidomide-containing regimen and must be intolerant or refractory to it, defined as occurrence of disease progression on lenalidomide or within 60 days after the last dose of treatment to lenalidomide.
h. Patient must have a measurable disease, defined as follows:
Serum monoclonal protein (M-protein) ≥0,5 g/dl by serum protein electrophoresis (sPEP) or
Urine light-chain excretion ≥200 mg/24-hour urine collection by urine protein electrophoresis (uPEP) or
Serum free light-chain (sFLC) levels \>100 mg/L (10 mg/dL) involved light chain and an abnormal kappa/lambdda FLC ratio (for patients whose disease is only measurable by serum FLC) i. Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status score of ≤ 2.
j. All prior relevant treatment-related toxicities (defined by National Cancer Institute- Common Toxicity Criteria for Adverse Events (NCI-CTCAE), version 5.0 must be ≤grade 1 at the time of enrolment.
k. Reproductive Status
Individuals of childbearing potential (IOCBP) must agree and adhere to all testing and contraception requirements for elranatamab based on SmPC and/or IB, and in the mezigdomide Clinical Trial Pregnancy Risk Awareness Checklist. IOCBPs must either commit to true abstinence\* from heterosexual contact (which must be reviewed on a monthly basis and source documented) or agree to use, and be able to comply with 2 effective forms of contraception without interruption: 28 days prior to starting study intervention, during treatment (including dose interruptions), and for at least 28 days after the last dose of mezigdomide\*\* or for at least 4 months (or 150 days) following last elranatamab dose whichever is longer.
Male participants must practice true abstinence\* (which must be reviewed on a monthly basis) or agree to use a condom during sexual contact with a pregnant individual or an IOCBP while participating in the study, during dose interruptions and for at least 28 days after the last dose of mezigdomide, or for at least 4 months (or 150 days) following last elranatamab dose whichever is longer, even if he has undergone a successful vasectomy.
\*True Abstinence is acceptable when this is in line with the preferred and usual lifestyle of the individual. Periodic abstinence (eg, calendar, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception.
Male participants must agree to refrain from donating semen or sperm while taking mezigdomide or during dose interruptions and that they will not donate semen or sperm for at least 28 days after the last dose of mezigdomide.
+2 more criteria
You may not qualify if:
Any serious medical condition or psychiatric illness that would interfere in understanding of the informed consent form.
Other plasma cell disorders/associated syndromes, e.g. plasma cell leukemia, POEMS, amyloidosis
Prior therapy with mezigdomide or any BCMA bispecific agent. Prior therapy with a BCMA-targeted CAR T-cell therapy or ADC are allowed if \>6 months have elapsed from the last dose.
Patients with non-adequate hematological and/or non-hematological parameters defined as the following laboratory abnormalities:
Absolute neutrophil count (ANC) \<1 x109/L without previous granulocyte colony-stimulating factor G-CSF support in the last 7 days prior to screening blood count.
Platelet count \<75 x109/L without previous platelet transfusions in the last 7 days prior to screening blood count.
Hemoglobin \<8.0 g/dl (Erythropoietin or RBC transfusions allowed).
Calculated or measured creatinine clearance / estimated glomerular filtration rate (eGFR) \<30 mL/min (calculated from the Cockcroft and Gault formula) (APPENDIX 5) or requiring dialysis.
Serum aspartate transaminase (AST): \> 2.5 x the upper limit of normal (ULN).
The following relevant diseases or adverse clinical conditions:
Uncontrolled cardiac arrhythmias (i.e., requiring a change in medication within the last 3 months or a hospital admission within the past 6 months) or clinically significant electrocardiogram abnormalities such as 2nd degree (Type II) or 3rd degree atrioventricular (AV) block.
Planned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
December 2032
Estimated
Planned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
October 28, 2026
Record last verified: 2026-10
Data Sharing
IPD Sharing
Will not share
Source record
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.